Immunotherapy: TARGETING OVARIAN CARCINOMA WITH GDT002, A FIRST-IN-CLASS γδTCR-BASED T CELL THERAPY - Middendorp, S; Drent, E; Bisso, A; Baardman, S; Verweij, D; Salcedo, E; Coomans, C; Braem, S; van de Weg, S; Meijer, M; Proost, N; van de Ven, M; et al. (Cytotherapy (Oxford, England), 2023)